Enobosarm

Drug Profile

Enobosarm

Alternative Names: GTx-024; MK-2866; Ostarine

Latest Information Update: 24 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GTx
  • Developer City of Hope National Medical Center; GTx; National Cancer Institute (USA)
  • Class Nitriles; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cachexia

Highest Development Phases

  • Phase II Breast cancer; Stress incontinence
  • Preclinical Duchenne muscular dystrophy
  • Discontinued Cachexia; Muscular atrophy

Most Recent Events

  • 09 Aug 2017 GTx plans a phase II trial for Urinary incontinence (NCT03241342)
  • 12 Jun 2017 Preliminary efficacy and adverse events data from a proof-of-concept phase II trial in Stress incontinence released by GTx
  • 15 May 2017 GTx completes enrolment in its phase II trial for Breast cancer (Metastatic disease, Recurrent, Late-stage disease) in USA (PO) (NCT02463032)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top